When Meningitis Strikes Twice Amanda Moyer, MD, presents her poster at RWCS 2024. https://t.co/hO8VkcqCkb https://t.co/9tfKI7dEs9

CD19 CAR T-Cell Therapy in Autoimmune Disease The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious. https://t.co/D53xeBdgsu https://t.co/dkrJ2CiSTl

Fever of Unknown Origin: Not Always an Infection Roel Sanchez Baez, MD presents his poster at RWCS 2024. https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A

Excess Cardiovascular Risk in Gout A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders. https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR

Can Biomarkers Improve Cardiovascular Risk Assessments in RA? The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis. https://t.co/NTI57kTtAy https://t.co/idf4qTtKcw

It's a Sore Subject Cindy Chiu, DO, presents her poster at RWCS 2024. https://t.co/Bl7mAL4grR https://t.co/9rLglObu4V

Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open. https://t.co/WApFsSzn1W https://t.co/jNv6MClCRk

Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. https://t.co/FJtWtaxXeG https://t.co/olcRoFZrBY

Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/YAjffGVATG https://t.co/5UWNpDNioT

As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9

In 2023, the FDA approved 956 generic drugs and issued 1,493 complete response letters; an improvement on 2022’s 914 approvals and 1,775 complete response letters. https://t.co/XnpQLbxJCr https://t.co/zzf63G4s2R

IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%). https://t.co/drFAtBG4ZU https://t.co/N8ixHS64HD